Navigation Links
Oncolytics(R) Biotech Inc. Completes Patient Enrolment in U.S. Phase 2 Sarcoma Study
Date:5/12/2009

avenous, multiple dose REOLYSIN in patients with bone and soft tissue sarcomas metastatic to the lung. REOLYSIN is delivered intravenously to patients at a dose of 3x1010 TCID50 for five consecutive days, every 28 days.

Eligible patients had to have a bone or soft tissue sarcoma metastatic to the lung deemed by their physician to be unresponsive to or untreatable by standard therapies. These included patients with osteosarcoma, Ewing sarcoma family tumours, malignant fibrous histiocytoma, synovial sarcoma, fibrosarcoma and leiomyosarcoma.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN, its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. Phase II sarcoma clinical trial and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the tolerability of REOLYSIN outside a controlled test, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, unc
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
3. ISI Increases West Coast Life Science and Biotech Support for Emerging Companies with Expansion in San Francisco and San Diego
4. Amyris Biotechnologies Co-Founder Neil Renninger Named to Technology Reviews Prestigious TR35 List of Top Young Innovators
5. Finkelstein Thompson LLP Announces GPC Biotech AG Investigation
6. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
7. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
8. Microchip Biotechnologies, Inc. Secures Exclusive License to Use New University of Alberta Technology for Developing Microfluidic Devices
9. Shareholder Class Action Filed Against GPC Biotech AG by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP
10. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
11. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... , PLEASANTON, Calif., Sept. 1 Thoratec Corporation ... circulatory support therapies to save, support and restore failing hearts, said ... & Co. Healthcare Conference on Wednesday, September 9. , , ... officer, will provide an update on the company beginning at 10 ...
... BALTIMORE, Sept. 1 Champions Biotechnology, Inc. ... development of advanced preclinical platforms and tumor specific data to ... agreement with a large biotechnology company for the evaluation of ... , , By maintaining the fundamental genotypic ...
... , , TUSTIN, Calif., Sept. 1 ... management will present at the Rodman & Renshaw 11th Annual Healthcare Conference ... will be held at the New York Palace Hotel in New York ... presentation will be available at the Investors section of Peregrine,s website at ...
Cached Biology Technology:Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 2Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 3Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2
(Date:4/17/2014)... detection cartridge developed at Sandia National Laboratories and recently ... faster and cheaper. , Bacillus anthracis , ... soils all over the world and can cause serious, ... The bacteria can survive in harsh conditions for decades. ... occur through skin contact, inhalation of spores or eating ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
(Date:4/17/2014)... honeybees in Europe, Asia and the United States are ... be impacting native honeybee populations at this time, according ... include including Nosema microsporidia and Varroa ... resilient to these invasive pests, which suggests to us ... Asia and the United States currently are not necessary ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... to develop new drugs, the pharmaceuticals industry is making ... natural biological transformation processes. One of the most important ... a bioreactor filled with a liquid culture medium. As ... conditions inside the bioreactor need to be monitored precisely. ...
... disciplines recently gathered to address a major question: what ... Of course, possible answers to this question raise even ... to alter local vegetation, how would this new landscape ... certainty would allow us to manage better our natural ...
... BioScience, researchers present a sophisticated new analysis ... on greenhouse gas emissions. The study, conducted by Thomas ... on how mandated increases in production of the biofuel ... and elsewhere. In response to the increased demand for ...
Cached Biology News:Clean sampling from bioreactors 2Networking initiative to support interdisciplinary research 2Networking initiative to support interdisciplinary research 3More maize ethanol may boost greenhouse gas emissions 2
... a proteolytic product of ... I which retains polymerization and ... but has lost 5 ->3 ... polymerization fidelity of the holoenzyme ...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
... E. coli strain containing an overproducing clone of ... the formation of a phosphodiester bond between juxtaposed ... DNA or RNA. It repairs single-stranded nicks in ... join both blunt-end and cohesive-end fragments of duplex ...
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
Biology Products: